How effective is it to switch among atypical antipsychotics? A randomized, open-label study of algorithm-based antipsychotic treatment to symptomatic patients with schizophrenia in a real-world clinical setting

被引：0
|
作者：
Suzuki, T.
Uchida, H.
Watanabe, K.
Tanabe, A.
Tsunoda, K.
Nomura, K.
Niou, S.
Takeuchi, H.
Yagi, G.
Kashima, H.
机构：
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[2] Inokashira Hosp, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2006年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 44 条
  • [1] How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone? - A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting
    Suzuki, Takefumi
    Uchida, Hiroyuki
    Watanabe, Koichiro
    Nomura, Kensuke
    Takeuchi, Hiroyoshi
    Tomita, Masayuki
    Tsunoda, Kenichi
    Nio, Shintaro
    Den, Ryoske
    Manki, Hiroshi
    Tanabe, Akira
    Yagi, Gohei
    Kashima, Haruo
    PSYCHOPHARMACOLOGY, 2007, 195 (02) : 285 - 295
  • [2] How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting
    Takefumi Suzuki
    Hiroyuki Uchida
    Koichiro Watanabe
    Kensuke Nomura
    Hiroyoshi Takeuchi
    Masayuki Tomita
    Kenichi Tsunoda
    Shintaro Nio
    Ryoske Den
    Hiroshi Manki
    Akira Tanabe
    Gohei Yagi
    Haruo Kashima
    Psychopharmacology, 2007, 195 : 285 - 295
  • [3] An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia
    Hirano, Jinichi
    Watanabe, Koichiro
    Suzuki, Takefumi
    Uchida, Hiroyuki
    Den, Ryosuke
    Kishimoto, Taishiro
    Nagasawa, Takashi
    Tomita, Yusuke
    Hara, Koichiro
    Ochi, Hiromi
    Kobayashi, Yoshimi
    Ishii, Mutsuko
    Fujita, Akane
    Kanai, Yoshihiko
    Goto, Megumi
    Hayashi, Hiromi
    Inamura, Kanako
    Ooshima, Fumiko
    Sumida, Mariko
    Ozawa, Tomoko
    Sekigawa, Kayoko
    Nagaoka, Maki
    Yoshimura, Kae
    Konishi, Mika
    Inagaki, Ataru
    Saito, Takuya
    Motohashi, Nobutaka
    Mimura, Masaru
    Okubo, Yoshiro
    Kato, Motoichiro
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 1553 - 1564
  • [4] Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: An open-label switch study
    Lindenmayer, JP
    Czobor, P
    Volavka, J
    Lieberman, JA
    Citrome, L
    Sheitman, B
    Chakos, M
    McEvoy, JP
    JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (10) : 931 - 935
  • [5] Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting
    Mueller, Simon M.
    Navarini, Alexander A.
    Goldust, Mohamad
    Brandt, Oliver
    Griffiths, Christopher E. M.
    Kleyn, Christine E.
    DERMATOLOGIC THERAPY, 2020, 33 (01)
  • [6] AMISULPRIDE IMPROVES OBSESSIVE-COMPULSIVE SYMPTOMS IN SCHIZOPHRENIA PATIENTS TAKING ATYPICAL ANTIPSYCHOTICS: AN OPEN-LABEL SWITCH STUDY
    Kim, Sung-Wan
    Shin, I. S.
    Kim, J. M.
    Yang, S. J.
    Youn, T.
    Yoon, J. S.
    SCHIZOPHRENIA BULLETIN, 2009, 35 : 367 - 367
  • [7] Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics - An open-label switch study
    Kim, Sung-Wan
    Shin, Il-Seon
    Kim, Jae-Min
    Yang, Su-Jin
    Hwang, Michael Y.
    Yoon, Jin-Sang
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2008, 28 (03) : 349 - 352
  • [8] Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: An open-label switch study
    Kim, S. -W.
    Pac, J. -W.
    Kim, J. -M.
    Shin, I. S.
    Yang, S. -J.
    Bae, K. -R.
    Kim, S. -Y.
    Hwang, M.
    Yoo, J. -A.
    Yoon, J. S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 133 - 133
  • [9] Prevalence of diabetes/cardiovascular risk factors among schizophrenia patients treated with atypical antipsychotics in a multicenter, randomized, naturalistic, open-label study (Schizophrenia Trial of Aripiprazole: STAR study)
    Litalien, Gilbert J.
    Blonde, Lawrence
    Hanssens, Linda
    McQuade, Robert
    DIABETES, 2006, 55 : A538 - A538
  • [10] Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, "real world" clinical trial
    Zhang, Cheng
    Yuan Yanbo
    Xue, Han
    Lei, Yang
    Xin, Zeng
    Yang Fude
    Zheng, Lu
    Wang Chuanyue
    Hong, Deng
    Zhao Jingping
    Xiang Yu-Tao
    Correll, Christoph U.
    Xin, Yu
    PSYCHIATRY RESEARCH, 2019, 273 : 631 - 640
12345